Phase 2Completed
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL)
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study (PEARL): A Prospective, Double-Blind, Placebo-Controlled Trial for Rapamycin in Healthy Individuals Assessing Safety and Efficacy in Reducing Aging Effects
- Sponsor
- AgelessRx (Industry)
- Enrolment
- 129 enrolled
- Conditions
- Aging
- Interventions
- Rapamycin; Placebo
- Ages
- adults, older adults
- Registry
- NCT04488601
From the registry
This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.
Primary outcomes
- Changes in visceral fat as measured by dual-energy x-ray absorptiometry (DXA) scan